Compare Nokia Corp (NOK) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Novo Nordisk A/S — how do they compare? Nokia Corp trades at $10.4 (market cap $56.99B), while Novo Nordisk A/S trades at $38.63 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 2.9× Nokia Corp's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 66 Days and Novo Nordisk A/S for 116 Days on average.
| NOK | NVO | |
|---|---|---|
Market Cap | $56.99B | $165.31B |
Volume | 69,968,204 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $16.83 | $63.98 |
52-Week Low | $5.18 | $35.29 |
Typical Hold Time | 66 Days | 116 Days |
Enterprise Value | $55.01B | $179.56B |
Dividend Yield | 1.61% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.285, down 3.15% today, with a bearish technical signal from moving averages and neutral oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89B with a net income margin of 3.47%. Recent news highlights partnerships in AI and satellite communications, including an expanded collaboration with Microsoft and a defense-focused satellite venture with ICEYE.
The stock presents a valuation challenge with a high P/E of 75.09, though analyst consensus is bullish with a $17.50 price target. Upside potential is supported by AI infrastructure demand and strategic partnerships, but risks include competitive pressures, execution on growth initiatives, and volatile cash flows. The current price is well below the consensus target, indicating significant projected upside if growth catalysts materialize.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
